Kibo Mining PLC’s (LON:KIBO) listing of its Imweru and Lubando gold mining assets in Tanzania is to take effect on 23 May.
A reverse takeover of Opera Investments is the method for the deal with the name of the company to be changed to Katoro Gold PLC to reflect the new business focus.
Aussie oil and gas major Origin Energy has bought-out Sasol from the Beetaloo basin shale venture in the Northern Territory. Origin’s stake in the project doubles to 70% as a result of the deal, while AIM-quoted Falcon Oil & Gas Ltd (LON:FOG) retains the other 30%.
ValiRx Plc (LON:VAL) is continuing discussions with potential partners over funding for the next stage of clinical studies for its two lead cancer drugs after good progress in 2016. The AIM-listed group has two drugs currently in clinical trial: VAL201 for prostate cancer; and VAL401 for lung cancer.
Strategic Minerals Plc (LON:SML) is to take full control of Central Australia Rare Earths, the company that own the Hanns Camp prospect in Western Australia. John Peters, Strategic’s managing director, said CARE’s tenements will need extra funding to explore fully, something it can provide from its booming Cobre tailings business in New Mexico.
Pizza franchise group DP Poland Plc (LON:DPP) has told investors it is trading in line with expectations, with a 21% increase in like-for-like system sales during the first quarter. DP Poland, in a statement ahead of today’s annual general meeting, highlighted that it has opened eight new stores in the year to date, taking its tally to 43 stores across 16 towns and cities.
SDX Energy Inc (LON:SDX) has given details of the deeper exploration target in the SD-1X well, in Egypt, where drilling is now complete. Having already made a significant gas discovery in shallower gas targets the company has now confirmed the presence of hydrocarbons and a working petroleum system in the deeper exploration target, though there wasn’t a sufficient amount of hydrocarbons to warrant further testing at this time.
ReNeuron Group Plc (LON:RENE) has presented encouraging new data relating to the characterisation and scale-up of its CTX cell-derived exosome therapy candidates at a leading scientific conference in London. Exosome therapy is being explored by ReNeuron both as a potential new nanomedicine targeting cancer and as a delivery system for gene therapy treatments.
Internet of things specialist Telit Communications Plc (LON:TCM) is set for an acquisition spree after a £39mln cash call. Telit said it had already identified companies in the IoT Services sector that it wanted to buy and with the new money will look to execute deals in the near to medium term.